Clinical trials indicate that sodium/glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i)
improve kidney function, yet, the molecular regulation of SGLT2 expression is incompletely …

Background Renal proximal tubular sodium and glucose reabsorption are regulated by the
sodium-glucose cotransporter (SGLT2). Changes in this transporter can play a role in …

Renal proximal tubular angiotensinogen (AGT) is increased by hyperglycemia (HG) in
diabetes mellitus, which augments intrarenal angiotensin II formation, contributing to the …

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

Pharmacological Na+-glucose linked cotransporter (SGLT) 2 inhibition is being examined as
a renal protection strategy in nondiabetic chronic kidney disease. We quantified renal SGLT …

Blood glucose-lowering treatment options generally target insulin action or beta-cell
function. In diabetes, expression of the sodium-glucose cotransporter-2 (SGLT2) genes is up …

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide.
Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the …

Sodium-glucose co-transporters (SGLTs) in the kidneys play a pivotal role in glucose
reabsorption. Several clinical and population-based studies revealed the beneficial effects …

Sodium‐dependent glucose cotransporters (SGLTs) have attracted considerable attention
as new targets for type 2 diabetes mellitus. In the kidney, SGLT2 is the major glucose uptake …

Na+-glucose cotransporter-2 (SGLT2) inhibitors are the new mainstay of treatment for
diabetes mellitus and cardiovascular diseases. Despite the remarkable benefits, the …